Are you Dr. Lubiniecki?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 105 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-2500Fax+1 215-728-3639
Summary
- Dr. Gregory Lubiniecki, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Minnesota. He is affiliated with Fox Chase Cancer Center.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2001
Johns Hopkins University School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2001 - 2024
NJ State Medical License 2004 - 2009
MN State Medical License 1999 - 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 38 citationsThe LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.Matthew H. Taylor, Emmett V. Schmidt, Corina E. Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi
Future Oncology. 2021-02-01 - 165 citationsLong-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 S...Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose Luis Perez-Gracia
Journal of Clinical Oncology. 2020-02-20 - 2069 citationsPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, op...Tony Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho
Lancet. 2019-05-04
Press Mentions
Merck’s Investigational Zilovertamab Vedotin in Combination with R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients with Diffuse Large B-cell LymphomaDecember 8th, 2024- FDA Approves Merck’s KEYTRUDA® (Pembrolizumab) plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)September 18th, 2024
- KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Combination with Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients with Unresectable, Non-Metastatic Hepatocellular CarcinomaSeptember 14th, 2024
- Join now to see all
Professional Memberships
- Member
